<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00628628</url>
  </required_header>
  <id_info>
    <org_study_id>2006-0918</org_study_id>
    <nct_id>NCT00628628</nct_id>
  </id_info>
  <brief_title>Rasburicase in Patients at Risk for Tumor Lysis Syndrome</brief_title>
  <official_title>Phase 2 Study of Rasburicase Administered by Two Different Schedules (Fixed Dosing vs. As Needed Dosing) in Patients at High Risk or Potential Risk for Tumor Lysis Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
      To determine the efficacy of rasburicase administered as a single dose followed by as needed&#xD;
      dosing (investigational arm) as compared to fixed dosing for 5 days (standard treatment arm)&#xD;
      in the treatment of patients at high risk or potential risk for tumor lysis syndrome.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        1. To evaluate the plasma uric acid area under the curve (AUC) from baseline through 7 days&#xD;
&#xD;
        2. To evaluate the incidence of renal insufficiency and electrolyte abnormalities.&#xD;
&#xD;
        3. To determine the safety and immunogenicity of rasburicase.&#xD;
&#xD;
        4. To evaluate the cost-effectiveness of the experimental treatment (investigational arm).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drug and TLS Rasburicase is designed to help decrease or prevent the high level of&#xD;
      uric acid that may occur during the start of chemotherapy. A high level of uric acid in the&#xD;
      blood may lead to decreased kidney function or kidney failure.&#xD;
&#xD;
      TLS occurs when high uric acid levels are caused by breakdown of tumor cells during the start&#xD;
      of chemotherapy. The dead tumor cells can release uric acid and cause other symptoms of&#xD;
      kidney failure, such as releasing large amounts of potassium and phosphorus (chemicals) into&#xD;
      the blood.&#xD;
&#xD;
      Screening Tests Before you can start treatment on this study, you will have &quot;screening&#xD;
      tests.&quot; These tests will help the doctor decide if you are eligible to take part in this&#xD;
      study.&#xD;
&#xD;
      Your complete medical history will be recorded. You will have a physical exam, including&#xD;
      measurement of your vital signs (blood pressure, heart rate, temperature, and breathing&#xD;
      rate), height, and weight.&#xD;
&#xD;
      Blood will be drawn (about 2 tablespoons) for routine tests. Women who are able to have&#xD;
      children must have a negative blood (using a sample from the routine blood draw) or urine&#xD;
      pregnancy test.&#xD;
&#xD;
      Study Groups If you are found to be eligible to take part in this study, you will be randomly&#xD;
      assigned (as in the toss of a coin) to 1 of 2 groups. There is an equal chance of being in&#xD;
      either group.&#xD;
&#xD;
      Group A Participants in Group A will receive rasburicase by vein, over 30 minutes, on Day 1&#xD;
      of Cycle 1 of chemotherapy. On Days 1-7 of Cycle 1 of chemotherapy, blood (about 2&#xD;
      tablespoons) will be drawn for routine tests, including a check of the level of uric acid in&#xD;
      your blood. During Days 2-5 of Cycle 1 of chemotherapy, you will only receive rasburicase&#xD;
      (once a day) if the levels of uric acid are high that day.&#xD;
&#xD;
      Group B Participants in Group B will receive rasburicase by vein, over 30 minutes, once a day&#xD;
      from Days 1-5 of Cycle 1 of chemotherapy. On Days 1-7 of Cycle 1 of chemotherapy, blood&#xD;
      (about 2 tablespoons) will be drawn for routine tests, including a check of the level of uric&#xD;
      acid in your blood.&#xD;
&#xD;
      Both Groups Treatment with rasburicase will only be given in Cycle 1 of chemotherapy. The&#xD;
      chemotherapy will be given at least 4 hours (up to 24 hours) after the first dose of&#xD;
      rasburicase.&#xD;
&#xD;
      Length of Study When your blood test results show that you do not have antibodies to&#xD;
      rasburicase, your participation in this study will be over. You will be taken off this study&#xD;
      if the TLS gets worse or intolerable side effects occur.&#xD;
&#xD;
      This is an investigational study. Rasburicase is commercially available, but it is not FDA&#xD;
      approved for treating TLS. It is FDA approved for pediatric patients with leukemia, lymphoma,&#xD;
      and solid tumor cancers who are receiving anti-cancer therapy that is expected to increase&#xD;
      the blood levels of uric acid (the result of cancer cells dying from treatment). For treating&#xD;
      TLS in adult patients, it has been authorized for use in research only. Up to 80 evaluable&#xD;
      patients will take part in this study. All will be enrolled at M. D. Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Plasma Uric Acid (UA) Response</measure>
    <time_frame>First cycle of chemotherapy, up to 5 days</time_frame>
    <description>Plasma UA response is defined as normalization of plasma UA levels within 48 hours after the start of study drug (rasburicase) and maintaining within the normal range after the final drug infusion on day 5. Plasma samples for UA were collected at baseline before rasburicase, 4- and 24-hours post-rasburicase, and daily during treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Tumor Lysis Syndrome</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>As Needed Rasburicase .15 mg/kg IV Over 30 Minutes On Day 1. Day 2-5, once daily as needed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed Dose Rasburicase .15 mg/kg IV Over 30 Minutes Daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>As Needed Rasburicase</intervention_name>
    <description>.15 mg/kg IV Over 30 Minutes On Day 1. Day 2-5, once daily as needed.</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Elitek™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fixed Dose Rasburicase</intervention_name>
    <description>.15 mg/kg IV Over 30 Minutes Daily</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Elitek™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with hematological malignancies (leukemia/lymphoma) at high risk or potential&#xD;
             risk for tumor lysis syndrome. High risk: hyperuricemia of malignancy (Uric acid&#xD;
             levels &gt;7.5); diagnosis of very aggressive lymphoma/leukemia based on Revised&#xD;
             European-American Lymphoma (REAL) classification; acute myeloid leukemia, chronic&#xD;
             myelocytic leukemia (CML) in blast crisis; high grade myelodysplastic syndrome only if&#xD;
             they have &gt;10% bone marrow blast involvement and given aggressive treatment similar to&#xD;
             acute myeloid leukemia (AML) (continued on #2)&#xD;
&#xD;
          2. (continued from # 1) Potential risk: diagnosis of aggressive lymphoma/leukemia based&#xD;
             on (REAL) classification. Plus one or more of the following criteria: lactate&#xD;
             dehydrogenase (LDH) &gt;/= 2 x upper limit of normal (ULN); Stage III-IV disease; Stage&#xD;
             I-II disease with at least 1 lymph node/tumor &gt;5cm in diameter.&#xD;
&#xD;
          3. ECOG performance status 0-3&#xD;
&#xD;
          4. Life expectancy &gt;3 months&#xD;
&#xD;
          5. Negative pregnancy test (females of child bearing potential) within &lt;/=2 weeks of&#xD;
             rasburicase dose and use of efficient contraceptive method (both males and females).&#xD;
             Pregnancy test may be performed on serum (HCG) or urine (HCG)&#xD;
&#xD;
          6. Signed written informed consent (approved by the Institutional Review Board/Ethics&#xD;
             Committee) obtained prior to study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient receiving any investigational drug for hyperuricemia within 30 days of planned&#xD;
             first treatment with rasburicase&#xD;
&#xD;
          2. Pregnancy or lactation&#xD;
&#xD;
          3. Known history of significant allergy problem or documented history of asthma or&#xD;
             asthmatic bronchitis&#xD;
&#xD;
          4. Known history of glucose-6-phosphate dehydrogenase deficiency&#xD;
&#xD;
          5. Known history of hemolysis and methemoglobinemia&#xD;
&#xD;
          6. Previous therapy with urate oxidase&#xD;
&#xD;
          7. Other conditions unsuitable for participation in the trial in the Investigator's&#xD;
             opinion&#xD;
&#xD;
          8. Unwillingness to comply with the requirements of the protocol&#xD;
&#xD;
          9. Use of allopurinol within 72 hours of the study entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saroj Vadhan-Raj, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center</description>
  </link>
  <results_reference>
    <citation>Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol. 2012 Jun;23(6):1640-5. doi: 10.1093/annonc/mdr490. Epub 2011 Oct 19.</citation>
    <PMID>22015451</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>February 25, 2008</study_first_submitted>
  <study_first_submitted_qc>February 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2008</study_first_posted>
  <results_first_submitted>May 31, 2013</results_first_submitted>
  <results_first_submitted_qc>May 31, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 1, 2013</results_first_posted>
  <last_update_submitted>May 31, 2013</last_update_submitted>
  <last_update_submitted_qc>May 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tumor Lysis Syndrome</keyword>
  <keyword>TLS</keyword>
  <keyword>hyperuricemia</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Acute myeloid leukemia</keyword>
  <keyword>Chronic myelocytic leukemia</keyword>
  <keyword>CML</keyword>
  <keyword>lactate dehydrogenase</keyword>
  <keyword>LDH</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>Rasburicase</keyword>
  <keyword>Elitek™</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tumor Lysis Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rasburicase</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: January 28, 2008 to March 8, 2010. All participants were recruited in a medical clinic setting at The UT MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Eighty-two patients were enrolled between February 2008 and February 2010. Two patients withdrew consent and 80 patients were randomized; 40 to the Arm A and 40 to the Arm B.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A: Single Dose</title>
          <description>As Needed Rasburicase .15 mg/kg IV Over 30 Minutes On Day 1. Day 2-5, once daily as needed.</description>
        </group>
        <group group_id="P2">
          <title>Group B: Daily Dose</title>
          <description>Fixed Dose Rasburicase .15 mg/kg IV Over 30 Minutes Daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A: Single Dose</title>
          <description>As Needed Rasburicase .15 mg/kg IV Over 30 Minutes On Day 1. Day 2-5, once daily as needed.</description>
        </group>
        <group group_id="B2">
          <title>Group B: Daily Dose</title>
          <description>Fixed Dose Rasburicase .15 mg/kg IV Over 30 Minutes Daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="27" upper_limit="82"/>
                    <measurement group_id="B2" value="58" lower_limit="27" upper_limit="81"/>
                    <measurement group_id="B3" value="60" lower_limit="27" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Plasma Uric Acid (UA) Response</title>
        <description>Plasma UA response is defined as normalization of plasma UA levels within 48 hours after the start of study drug (rasburicase) and maintaining within the normal range after the final drug infusion on day 5. Plasma samples for UA were collected at baseline before rasburicase, 4- and 24-hours post-rasburicase, and daily during treatment.</description>
        <time_frame>First cycle of chemotherapy, up to 5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A: Single Dose</title>
            <description>As Needed Rasburicase .15 mg/kg IV Over 30 Minutes On Day 1. Day 2-5, once daily as needed.</description>
          </group>
          <group group_id="O2">
            <title>Group B: Daily Dose</title>
            <description>Fixed Dose Rasburicase .15 mg/kg IV Over 30 Minutes Daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Plasma Uric Acid (UA) Response</title>
          <description>Plasma UA response is defined as normalization of plasma UA levels within 48 hours after the start of study drug (rasburicase) and maintaining within the normal range after the final drug infusion on day 5. Plasma samples for UA were collected at baseline before rasburicase, 4- and 24-hours post-rasburicase, and daily during treatment.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years, 1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group A: Single Dose</title>
          <description>As Needed Rasburicase .15 mg/kg IV Over 30 Minutes On Day 1. Day 2-5, once daily as needed.</description>
        </group>
        <group group_id="E2">
          <title>Group B: Daily Dose</title>
          <description>Fixed Dose Rasburicase .15 mg/kg IV Over 30 Minutes Daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Methemoglobinemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyperphosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Clinical tumor lysis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Laboratory tumor lysis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased serum creatinine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Renal events requiring dialysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Saroj Vadhan-Raj, MD / Professor</name_or_title>
      <organization>The University of Texas (UT) MD Anderson Cancer Center</organization>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

